Conditions: Detrusor Overactivity Overactive Bladder
Keywords: Vesicare Solifenacin Detrusor Overactivity Urinary Nerve Growth Factor Overactive Bladder Bladder wall thickness
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 547
Healthy volunteers: no

Brief summary:
The purpose is to see if solifenacin has any effect on bladder wall thickness and urine inflammatory marker measurements after 12 weeks of treatment.

Detailed description:
Participants satisfying all selection criteria at the end of the 2-week, single blind, placebo run-in period were randomized to receive 12-week double-blind treatment with solifenacin 5 mg or 10 mg once daily, or placebo.

Arms:
arm 1: Participants received 2 placebo tablets once daily for 12 weeks. arm 2: Participants received one 5 mg solifenacin tablet and one placebo tablet, once daily for 12 weeks. arm 3: Participants received two 5 mg solifenacin tablets once daily for 12 weeks.

Interventions: intervention 1: Placebo intervention 2: solifenacin
Intervention descriptions: intervention 1: Matching solifenacin placebo tablet intervention 2: Tablet for oral administration

Protocol document: